Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.
4.
5.

Cimetidine preserves non-specific immune function after colonic resection for cancer.

Adams WJ, Morris DL, Ross WB, Lubowski DZ, King DW, Peters L.

Aust N Z J Surg. 1994 Dec;64(12):847-52.

PMID:
7980260
6.

Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement.

Macchetti AH, Marana HR, Silva JS, de Andrade JM, Ribeiro-Silva A, Bighetti S.

Clinics (Sao Paulo). 2006 Jun;61(3):203-8. Epub 2006 Jun 30.

7.

Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes.

Kelly MD, King J, Cherian M, Dwerryhouse SJ, Finlay IG, Adams WJ, King DW, Lubowski DZ, Morris DL.

Cancer. 1999 Apr 15;85(8):1658-63.

PMID:
10223557
8.

Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases.

Gulubova M, Manolova I, Kyurkchiev D, Julianov A, Altunkova I.

APMIS. 2009 Dec;117(12):870-9. doi: 10.1111/j.1600-0463.2009.02547.x.

PMID:
20078551
9.
10.

Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer.

Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Smith CV, Pecorelli S, Radominska-Pandya A, Cannon MJ, Parham GP.

Gynecol Obstet Invest. 2001;51(4):254-61.

PMID:
11408737
12.

Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.

Van den Hove LE, Van Gool SW, Van Poppel H, Baert L, Coorevits L, Van Damme B, Ceuppens JL.

Clin Exp Immunol. 1997 Sep;109(3):501-9.

13.

Phenotypical and functional differences of tumor-infiltrating lymphocytes from human colorectal cancers induced by costimulation with rIL-2 and rIL-4 in vitro.

Keller H, Wimmenauer S, Rahner S, Von Kleist S, Farthmann EH.

Anticancer Res. 1996 Nov-Dec;16(6B):3565-70.

PMID:
9042222
14.

Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells.

Diederichsen AC, Hjelmborg Jv, Christensen PB, Zeuthen J, Fenger C.

Cancer Immunol Immunother. 2003 Jul;52(7):423-8. Epub 2003 Apr 15.

PMID:
12695859
15.

Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.

Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Ménégaux F, Rosenzwajg M, Lemoine F, Klatzmann D, Taieb J.

Gut. 2009 Apr;58(4):520-9. doi: 10.1136/gut.2008.158824. Epub 2008 Nov 20.

PMID:
19022917
16.

Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content.

Ye SW, Wang Y, Valmori D, Ayyoub M, Han Y, Xu XL, Zhao AL, Qu L, Gnjatic S, Ritter G, Old LJ, Gu J.

J Clin Immunol. 2006 Sep;26(5):447-56. Epub 2006 Sep 12.

PMID:
16967323
17.
18.

Characterization of tumour-infiltrating lymphocytes and apoptosis in colitis-associated neoplasia: comparison with sporadic colorectal cancer.

Michael-Robinson JM, Pandeya N, Walsh MD, Biemer-Huttmann AE, Eri RD, Buttenshaw RL, Lincoln D, Clouston AD, Jass JR, Radford-Smith GL.

J Pathol. 2006 Feb;208(3):381-7.

PMID:
16315333
19.

Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer.

Wagner P, Koch M, Nummer D, Palm S, Galindo L, Autenrieth D, Rahbari N, Schmitz-Winnenthal FH, Schirrmacher V, Büchler MW, Beckhove P, Weitz J.

Ann Surg Oncol. 2008 Aug;15(8):2310-7. doi: 10.1245/s10434-008-9971-5. Epub 2008 Jun 3. Erratum in: Ann Surg Oncol. 2009 Apr;16(4):1084. Rahbari, Nuh [added].

PMID:
18521684
20.

The adaptive immune response to colorectal cancer: from the laboratory to clinical practice.

Curtis NJ, Primrose JN, Thomas GJ, Mirnezami AH, Ottensmeier CH.

Eur J Surg Oncol. 2012 Oct;38(10):889-96. doi: 10.1016/j.ejso.2012.05.011. Epub 2012 Jun 19. Review.

PMID:
22721580

Supplemental Content

Support Center